Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service radiofrequency ablation (facet, genicular, basivertebral) cases in Idaho: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 27 | 1,648 | 37% |
| 2020 | 27 | 2,155 | 40% |
| 2021 | 27 | 2,210 | 43% |
| 2022 | 25 | 2,082 | 47% |
| 2023 | 27 | 1,961 | 50% |
| 2024 | 27 | 2,085 | 52% |
| 2025 from claims | – | 2,298 2,109–2,431 | 54% |
| 2026 forecast | – | 2,663 2,343–3,073 | 49% |
| 2027 forecast | – | 2,845 2,432–3,390 | 49% |
| 2028 forecast | – | 3,039 2,536–3,721 | 49% |
| 2029 forecast | – | 3,246 2,652–4,071 | 49% |
| 2030 forecast | – | 3,468 2,779–4,445 | 48% |
Facet, genicular, and basivertebral nerve ablation. Professional codes (what the surgeon bills): CPT 64635, 64633, 64624, 64625, 64628.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 66% of the cases CMS names in Idaho; 15 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 58% hospital outpatient, 31% surgery center, 11% office. The share outside the hospital has moved −13 pts since 2019.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 375 | 24,956+2.5%/yr | +2.5%/yr | 7.1 | 86% | 32,700 in 2030+4.6%/yr |
| Arizona | 185 | 17,395+0.3%/yr | +0.3%/yr | 22.4 | 93% | 19,600 in 2030+2%/yr |
| Utah | 70 | 6,327+1.2%/yr | +1.2%/yr | 27.5 | 82% | 7,570 in 2030+3%/yr |
| Colorado | 95 | 6,258+2.1%/yr | +2.1%/yr | 12.2 | 84% | 8,230 in 2030+4.7%/yr |
| Washington | 75 | 4,700−0.3%/yr | −0.3%/yr | 5.9 | 77% | 5,550 in 2030+2.8%/yr |
| Nevada | 54 | 3,899−4.7%/yr | −4.7%/yr | 12.9 | 98% | 4,350 in 2030+1.8%/yr |
| Oregon | 49 | 3,673+3.6%/yr | +3.6%/yr | 8.3 | 97% | 5,130 in 2030+5.7%/yr |
| New Mexico | 39 | 2,542+2.5%/yr | +2.5%/yr | 10.5 | 73% | 3,290 in 2030+4.4%/yr |
| Montana | 25 | 973−0.6%/yr | −0.6%/yr | 5.0 | 49% | 1,190 in 2030+3.4%/yr |
| Alaska | 10 | 623−2.3%/yr | −2.3%/yr | 5.2 | 92% | 780 in 2030+3.7%/yr |
| Wyoming | 5 | 424+10%/yr | +10%/yr | 3.8 | 51% | 1,010 in 2030+16%/yr |
| Hawaii | 2 | 164−13%/yr | −13%/yr | 1.2 | 95% | 250 in 2030+7.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral nerve stimulation & intrathecal pumps | 4 | 403+11%/yr | +11%/yr | 1.82.0× | 20% | 790 in 2030+12%/yr |
| Spinal cord & DRG stimulation | 7 | 175−2.7%/yr | −2.7%/yr | 0.81.3× | 46% | 200 in 2030+1.9%/yr |
Radiofrequency ablation (facet, genicular, basivertebral) in every state, and its device makers · Every procedure market in Idaho · Every state · Compare with California
Boston Scientific leads with 79% of company spending on these surgeons in 2025, +41 pts on 2024.
In 2025, 6 companies reported engagement with Idaho’s surgeons worth $32K in consulting, speaking, meals and travel tied to these products, about $1,184 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.